Clinical Trial Update: An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease [Phase 3]

View source ↗

Summary

Open-label extension study of GA-GCB enzyme replacement therapy in adults with Type 1 Gaucher disease; phase 3 completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• GA-GCB ERT (GA-GCB enzyme replacement therapy)

Snippet

Sponsor: Shire | Conditions: Gaucher Disease, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2014-01-28